Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Debt / NOTE 3.000%10/1
-
Number of holders
-
14
-
Total 13F principal, excl. options
-
162,120,500
-
Principal change
-
-17,068,500
-
Total reported value, excl. options
-
$168,019,191
-
Value change
-
-$24,429,782
-
Number of buys
-
6
-
Number of sells
-
-6
-
Price
-
$1.04
Significant Holders of KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 as of Q1 2021
17 filings reported holding 48576UAA4 - KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 as of Q1 2021.
KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 has 14 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $162,120,500 of principal
.
Largest 10 bondholders include CITADEL ADVISORS LLC ($48,300,000 of principal), Farallon Capital Management, L.L.C. ($25,000,000 of principal), LAZARD ASSET MANAGEMENT LLC ($22,500,000 of principal), Davidson Kempner Capital Management LP ($20,000,000 of principal), STEELHEAD PARTNERS LLC ($16,000,000 of principal), CAPSTONE INVESTMENT ADVISORS, LLC ($13,500,000 of principal), Opti Capital Management, LP ($9,000,000 of principal), CNH PARTNERS LLC ($4,100,000 of principal), JPMORGAN CHASE & CO ($2,990,000 of principal), and CREDIT SUISSE AG/ ($517,000 of principal).
This table shows the top 14 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.